Figure 4.

S1R protects against ferroptosis in HCC cells. A, Indicated HCC cells were treated with erastin (10 μmol/L) and sorafenib (5 μmol/L) with or without cell death inhibitors (ferrostatin‐1, 1 μmol/L; ZVAD‐FMK, 10 μmol/L; necrosulfonamide, 0.5 μmol/L) for 24 h and cell viability was assayed (n = 3, *P < .05 vs erastin or sorafenib treatment group). B‐D, Indicated HCC cells were treated with erastin (10 μmol/L) or sorafenib (5 μmol/L) for 24 h. The levels of malondialdehyde (MDA), Fe2+ and glutathione (GSH) were assayed (n = 3, *P < .05 vs control shRNA group). E‐G, Indicated HCC cells were treated with erastin (10 μmol/L) or sorafenib (5 μmol/L) with or without BD1063 (10 μmol/L), BD1047 (10 μmol/L) or PRE‐084 (20 μmol/L) for 24 h. The levels of MDA, Fe2+ and GSH were assayed (n = 3, *P < .05 vs erastin or sorafenib treatment group)